IL-17 Blockade to Decrease irAEs (REPLAY)

The primary objective of this study is to determine the safety and feasibility of administering an IL-17A (human IgG1κ) monoclonal antibody, (Secukinumab, Cosentyx®) to participants with metastatic melanoma who have previously received immune checkpoint inhibitor (ICI) therapy, experienced an immune related adverse event (colitis, hepatitis, skin rash, psoriatic arthritis) to ICI, and are re-initiating ICI therapy.

NCT Number	NCT07237594
Lead Sponsor	Duke University
Conditions	Metastatic Melanoma
Enrollment	4 participants
Start Date	2026-03-12
Primary Completion	2027-06-30 (estimated)
Study Completion	2030-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-04